Secondary prevention strategies aim to prevent further deterioration in those who have been diagnosed with cardiovascular disease.4 The reduction of risk of a major coronary event or death has been quantified (Box 2).4 These benefits are likely to apply to Aboriginal and Torres Strait Islander people.
Smoking cessation
Aboriginal and Torres Strait Islander people are approximately twice as likely to smoke as other Australians. Addressing this risk factor is likely to have a substantial impact on reducing morbidity and premature death rates. In general practice, a brief intervention counselling approach is recommended.9 Nicotine replacement therapy is available on the Pharmaceutical Benefits Scheme (PBS) for Aboriginal and Torres Strait Islander patients. The use of other drugs to assist in smoking cessation requires careful consideration of the benefits and risks for the individual patient. There is also evidence in Aboriginal and Torres Strait Islander communities of the efficacy of community-based approaches.9
Box 1
Recommended approaches to cardiovascular disease in Aboriginal and Torres Strait Islander people
Screening and prevention
Individual risk assessment every 1–2 years from age 18 years including:9
- measurement of blood pressure, weight, body mass index, waist circumference, pulse for atrial fibrillation, fasting lipid and blood glucose, and urine testing for proteinuria
- calculation of absolute cardiovascular risk from age 35 years5
- promotion of healthy diet, weight control, physical activity, smoking cessation and moderation of alcohol consumption
Treatment
Early use of antihypertensives4– consider ACE inhibitors or angiotensin receptor antagonists as first-line drugs
Start treatment with cholesterol-lowering drugs when LDL cholesterol remains >2.5 mmol/L after lifestyle modification12
Cholesterol-lowering drugs may be prescribed on the Pharmaceutical Benefits Scheme:
- at any lipid level for patients with diabetes
- if total cholesterol >6.5 mmol/L or total cholesterol >5.5 mmol/L and HDL cholesterol <1 mmol/L
Box 2
Relative reduction in risk of major coronary event or death following secondary prevention activities 4
67% risk reduction for people under 65 years who have
never smoked
40% risk reduction for people 65 years and over who have
never smoked
22% risk reduction with ACE inhibitors
20% risk reduction with beta blockers
20% risk reduction if cholesterol controlled
20% risk reduction in people who are physically active
19% risk reduction with aspirin
14% risk reduction if blood pressure controlled
Nutrition and physical activity
Adoption of traditional dietary and food gathering practices has been shown to reduce risk factors for metabolic syndrome.10 For most Aboriginal and Torres Strait Islander people this is not possible. There is also often difficulty in accessing affordable, healthy food.6 Community-based programs may assist in improving both access to and acceptability of healthy foods. Reduction in alcohol consumption may reduce the risk of cardiovascular disease through its impact on diet, blood pressure and weight.5 It may also increase adherence to other risk reduction measures.
Regular physical activity prevents the development of risk factors for cardiovascular disease. When combined with other secondary prevention strategies in cardiac rehabilitation programs it has been shown to reduce cardiovascular mortality.4
Pharmacological management
Recommendations for pharmacological management for those at risk or with a past history of cardiovascular disease are similar to those for non-indigenous Australians.11 Aspirin in a dose of 75–150 mg/day reduces the risk of serious vascular events in those who have been diagnosed with cardiovascular disease. For those who are intolerant or allergic to aspirin, clopidogrel is an appropriate alternative.11
In recognition of the risk for Aboriginal and Torres Strait Islander people, cholesterol-lowering drugs are available through the PBS at lower thresholds than for other patients. 'Statin' therapy is recommended for Aboriginal and Torres Strait Islander patients if their low density lipoprotein cholesterol remains above 2.5 mmol/L after lifestyle modification.12
Early treatment with antihypertensive medication is recommended for Aboriginal and Torres Strait Islander patients with hypertension.13 While the first choice of drug depends on comorbidities and contraindications, in Aboriginal and Torres Strait Islander patients, given the high prevalence of diabetes, an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor antagonist is recommended.4
Polypill formulations including combinations of the recommended pharmaceutical drugs are currently being trialled to evaluate their usefulness as an aid to adherence to the long-term use of multiple drugs. The results of these studies are likely to inform best practice guidelines in the future.